Immunovative Inc. Files for Name and Symbol Change; After Necessary Approvals, Company Will Be Called: Tauriga Sciences, Inc.

Mon Mar 4, 2013 8:26am EST

* Reuters is not responsible for the content in this press release.

  NEW YORK, NY, Mar 04 (Marketwire) -- 
Immunovative Inc. (OTCQB: IMUN) or ("the Company") today announced that
it has filed documents with both the State of Florida and Financial
Industry Regulatory Authority ("FINRA") to effect a name change from
"Immunovative, Inc." to "Tauriga Sciences, Inc."

    The articles of amendment were submitted to the State of Florida on
February 22, 2013 and the corporate action application was submitted to
FINRA on February 28, 2013. After receiving the necessary approvals, the
Company will be called Tauriga Sciences, Inc ("Tauriga"). In addition the
Company will request, in connection with the FINRA process, a new trading
symbol to reflect the corporate name change and will disclose the new
symbol as soon as possible.

    The Company is also constructing its new corporate website, which will
exist under the following new URL address: (www.taurigasciences.com). As
soon as the new corporate website is launched, the Company will notify
shareholders through a press release. As previously stated, the Company
anticipates that it will continue to operate in the biotechnology or
medical device sector.

    Commenting on the name and symbol change, the Company's CEO Seth M. Shaw
commented, "The Company and its management are excited to capitalize on
potential opportunities available to us, with the goal of both restoring
and creating lasting shareholder value."

    About Immunovative Inc.

    On February 20, 2013, Immunovative, Inc. filed a Form 8K to notify
shareholder that the Company entered into a Settlement Agreement and
Release with ITL (the "Settlement Agreement"). The Settlement Agreement
resolves all claims brought by the Company against ITL. The Company's
current focus is to evaluate potential opportunities in the biotechnology
and/or medical device industry, however the Company will consider other
potential sectors if deemed in the best interest of shareholders.
Additionally on March 04, 2013, the Company announced that it filed for a
name and symbol change, such that the Company has changed its name to
Tauriga Sciences Inc. and is awaiting its new trading symbol. The new
corporate website is under construction and shall be launched at a future
date under the URL address: www.taurigasciences.com. 

    DISCLAIMER:

    Forward-Looking Statements: Except for statements of historical fact,
this news release contains certain "forward-looking statements" as
defined by the Private Securities Litigation Reform Act of 1995,
including, without limitation expectations, beliefs, plans and objectives
regarding the development, use and marketability of products. Such
forward-looking statements are based on present circumstances and on
IMUN's predictions with respect to events that have not occurred, that
may not occur, or that may occur with different consequences and timing
than those now assumed or anticipated. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors, and are
not guarantees of future performance or results and involve risks and
uncertainties that could cause actual events or results to differ
materially from the events or results expressed or implied by such
forward-looking statements. Such factors include general economic and
business conditions, the ability to successfully develop and market
products, consumer and business consumption habits, the ability to fund
operations and other factors over which IMUN has little or no control.
Such forward-looking statements are made only as of the date of this
release, and IMUN assumes no obligation to update forward-looking
statements to reflect subsequent events or circumstances. Readers should
not place undue reliance on these forward-looking statements. Risks,
uncertainties and other factors are discussed in documents filed from
time to time by IMUN with the Securities and Exchange Commission.

    

Contact:
For more information please contact:

Mr. Seth M. Shaw
Chairman & Chief Executive Officer
Immunovative, Inc.
New York: +1-917-796-9926
Montreal: +1-514-840-3697
Email: sethsms47@aol.com 

Copyright 2013, Marketwire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.